Files
Download Full Text (18.3 MB)
Contents
- Antiangiogenic Agents: Changing the Nature of Cancer Treatment
- DiaLog: Angiogenesis Research: Looking for New Ways to Measure Success, by Roy S. Herbst, MD, PhD, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology
- House Call: Overcome Fears of Cancer Recurrence by Taking Action
- Recognition Spurs Prevention of Osteoporosis in Patients with Cancer
- Protocols: Clinical Trials of Antiangiogenic Agents
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Publication Date
5-2001
Publisher
The University of Texas MD Anderson Cancer Center
City
Houston, Texas
Keywords
O'Reilly, Michael; Folkman, M. Judah; Herbst, Roy; Fidler, Isaiah J., 1936-; Yang, David J.; Guerra, Mercedes; Ellis, Lee M.; Sellin, Rena; Abbruzzese, James L.; Angiogenesis Inhibitors; Microvessels; Endostatins; Fibroblast Growth Factors; Interferon-alpha; Matrix Metalloproteinase 9; Interleukin-8; Vascular Endothelial Growth Factors; Clinical Trials as Topic; Angiostatins; Endostatins; Biopsy; Positron-Emission Tomography; Cytokines; Lymphoma; Leukemia; Glucocorticoids; Osteoporosis; Bone Resorption; Prostatic Neoplasms; Breast Neoplasms; Hormone Replacement Therapy; Raloxifene Hydrochloride; Alendronate; Calcitonin; Surveys and Questionnaires; Cancer Survivors.
Disciplines
History of Science, Technology, and Medicine | Oncology
Recommended Citation
O'Suilleabhain, Kate; Herbst, Roy S. MD, PhD; and Wright, Kerry L., "OncoLog, Volume 46, Number 05, May 2001" (2001). OncoLog MD Anderson's Report to Physicians (All issues). 95.
https://openworks.mdanderson.org/oncolog/95
Conditions Governing Access
Open
